Early Artificial Lateral Prosthesis

Official title

Treatment of Lateral Knee Joint Pain with Artificial Lateral Meniscus Prosthesis After Meniscectomy

Overview

The device subject to this clinical investigation has been developed for treating patients with a history of partial or total meniscectomy, who suffer from symptomatic unicompartmental pain in the meniscus-deficient knee: the post-meniscectomy pain syndrome. The intended purpose of the system is to replace the lateral native meniscus and its function after meniscectomy by distributing tibio-femoral loads and provide a clinically relevant reduction of pain and improvement of joint function.

Interventions

• Device Implantation of lateral meniscus prosthesis
  Implantation of a lateral meniscus prosthesis after meniscectomy.

Primary outcome measures

• Adverse events [Time frame: 12 months after implantation.]
• Implant integrity [Time frame: 12 months after implantation.]

Secondary outcome measures (12)

• KOOS [Time frame: 24 months.]
• Lysholm [Time frame: 24 months.]
• OKS [Time frame: 24 months.]
• EQ-5D-5L [Time frame: 24 months.]
• WORQ [Time frame: 24 months.]
• SF-36 [Time frame: 24 months.]
• Likert - Patient satisfaction [Time frame: 24 months.]
• Tegner Activity Scale [Time frame: 24 months.]
• IKDC Knee Examination Form [Time frame: 24 months.]
• Knee X-ray (weight-bearing) [Time frame: 24 months.]
• Knee X-ray (weight-bearing, long-leg) [Time frame: 24 months.]
• Knee X-ray (non-weight-bearing, supine) [Time frame: 24 months.]

Eligibility criteria

Inclusion criteria

• Is aged 18 to 70 years (inclusive) at the time of screening
• Has a history of partial or total meniscectomy
• Has post-meniscectomy pain syndrome (defined as symptomatic unicompartmental pain in the meniscus- deficient knee without severe cartilage damage- Kellgren \& Lawrence grade 3-4) in the lateral compartment as confirmed by patient history and MRI
• Has a KOOS Pain of ≤ 75 at the time of screening
• Failed conservative treatment options (non-operative treatments of the knee, i.e., self-management exercise programs, physical therapy, braces, pain medication, and intra-articular corticosteroids)
• Has neutral alignment < ± 3° of the mechanical axis
• Is willing to be implanted with the LMP System and to comply with instruction for use
• Is able and willing to do the study required follow-up visits, questionnaires, X-rays, and MRI
• Is able and willing to understand and sign the study Informed Consent Form
• Is able to read and understand the national language of the country in which the clinical site is located

Exclusion criteria

• Has progressed knee osteoarthritis, Kellgren \& Lawrence grade 3- 4 in the lateral compartment
• Has evidence of a modified Outerbridge Grade IV cartilage loss on the lateral tibial plateau or femoral condyle that potentially could contact the meniscus prosthesis
• Has medial compartment pain and Grade III or Grade IV modified Outerbridge cartilage score in the medial compartment
• Has a varus or valgus knee deformity of > 3°
• Has a valgus alignment that is not passively correctable
• Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
• Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
• Has patellar compartment pain and Grade III or Grade IV modified Outerbridge cartilage score in the patellar compartment
• Had an ACL reconstruction performed < 9 months prior to surgery
• Has a BMI > 35 at the time of screening
• Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the lateral meniscus prosthesis
• Has a knee flexion contracture > 10°
• Has flexion < 90°
• Had a knee alignment correction osteotomy < 9 months ago
• Has insufficiency fractures or avascular necrosis of the lateral compartment
• Has an active infection or tumor (local or systemic)
• Has any type of knee joint inflammatory disease including Sjogren's syndrome
• Has neuropathic knee osteoarthropathy, also known as Charcot joint
• Has any medical condition that does not allow possible arthroscopy of the knee
• Has neurological deficit (sensory, motor, or reflex)
• Anticipates having another lower extremity surgery during the study period
• Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
• Has received any corticosteroid knee injections ≤ 3 months prior to surgery
• Has proven osteoporosis
• Is on immunostimulating or immunosuppressing agents
• Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or study outcomes (e.g. have a leg length discrepancy > 2.5 cm \[1 inch\], causing a noticeable limp)
• Is a female who is lactating, expecting, or is intending to become pregnant during the study period
• Is an active smoker at the time of surgery
• Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
• Has a condition or be in a situation that, in the Investigator's opinion, may confound the clinical investigation results, may risk the safety of the patient, or may interfere significantly with the subject's participation in the clinical investigation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Other

Study locations

Netherlands · 1 center

• Radboudumc — Nijmegen

Identifiers

NCT: NCT06705985 · AM-101

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗